Multivariate analysis for serologic response in patients with CLL
| Variable . | OR . | 95% CI . | P . |
|---|---|---|---|
| Age ≤65 y | 3.17 | 1.16-8.67 | .025 |
| Female sex | 3.66 | 1.46-9.18 | .006 |
| Mutated IGHV | 1.39 | 0.47-4.10 | .543 |
| β2-microglobulin ≤3.5 mg/dL | 1.36 | 0.36-5.19 | .645 |
| Lack of active therapy | 6.59 | 2.30-18.86 | <.001 |
| Serum IgG level ≥550 mg/dL | 3.70 | 1.08-12.66 | .037 |
| Serum IgM level ≥40 mg/dL | 2.92 | 1.21-7.02 | .017 |
| Serum IgA level ≥80 mg/dL | 1.09 | 0.41-2.94 | .862 |
| Variable . | OR . | 95% CI . | P . |
|---|---|---|---|
| Age ≤65 y | 3.17 | 1.16-8.67 | .025 |
| Female sex | 3.66 | 1.46-9.18 | .006 |
| Mutated IGHV | 1.39 | 0.47-4.10 | .543 |
| β2-microglobulin ≤3.5 mg/dL | 1.36 | 0.36-5.19 | .645 |
| Lack of active therapy | 6.59 | 2.30-18.86 | <.001 |
| Serum IgG level ≥550 mg/dL | 3.70 | 1.08-12.66 | .037 |
| Serum IgM level ≥40 mg/dL | 2.92 | 1.21-7.02 | .017 |
| Serum IgA level ≥80 mg/dL | 1.09 | 0.41-2.94 | .862 |